Showing 321-330 of 9539 results for "".
Optimizing Absorption of Oral Isotretinoin
https://practicaldermatology.com/columns/clinical-focus-1/optimizing-absorption-of-oral-isotretinoin/23066/An update on lidose-isotretinoin and the ability to enhance absorption in the absence of high-fat meals.Effective Communication: Achieve Results You Want
https://practicaldermatology.com/topics/practice-management/effective-communication-achieve-results-you-want/19593/Kalyani Marathe, MD describes the Path to Action plan that can help you improve your communication skills—whether you're presenting, consulting with colleagues, or talking to patients. She offers tips for assessing your skills and finding ways to change your approach when needed.Ask an Expert: Sheila Fallon Friedlander, MD on the Molluscum Pipeline
https://practicaldermatology.com/topics/general-topics/ask-an-expert-sheila-fallon-friedlander-md-on-the-molluscum-pipeline/19006/Sheila Fallon Friedlander, MD talks to host Adam Friedman, MD about the pipeline of treatments for molluscum in pediatric patients. From NewDermMD.DermWireTV: AIRE SkinStore, Telehealth Cuts Consult Wait Times, Social Media and Realistic Expectations
https://practicaldermatology.com/topics/practice-management/dermwiretv-aire-skinstore-telehealth-cuts-consult-wait-times-social-media-and-realistic-expectations/19874/Launching with seven skincare brands, AIRE SkinStore allows dermatologists across the country to curate product recommendations, while providing discounts for their patients, says creator Dhaval Bhanusali, MD. Use of store-and-forward telemedicine can cut wait times for dermatology consults from 84How does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.Emerging Insights into the Immunologic Subtypes of Atopic Dermatitis in Children
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37157/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, discusses new understandings regarding the immunologic subtypes of atopic dermatitis and how they should influence treatment selection.AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anExpanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.Eczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, and